Nanobiotix S.A.
NBTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$34.53
KIRA · Stoqly’s AI analyst, in plain words
- Nanobiotix S.A. had $36.8M of revenue in fiscal 2025. Over five years, revenue changed +66.6% a year on average.
- Its operating margin was −33.2%, down 984.3 pts: of every 100 in sales, about −33 is left after running the business.
- Nanobiotix S.A. lost $27.0M in fiscal 2025.
- Free cash flow was −$38.3M in fiscal 2025, −104.2% of revenue.
Market cap
$1.65T
P/E
—
Revenue
$36.8M
Net income
−$27.0M
Free cash flow
−$38.3M
Operating margin
−33.2%
Nanobiotix S.A. in 30 seconds · fiscal 2025
Does it make a profit?
−73.5%
No. It lost money last year.
Does profit turn into cash?
−104.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nanobiotix S.A. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 31, 2026
- Legal name
- Nanobiotix S.A.
- CIK
- 0001760854
Nanobiotix S.A. · NBTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.1M | $5.0M | $39.2M | −$7.8M | $36.8M |
| Revenue growth | 9.3% | 60.3% | 680.0% | −119.9% | — |
| Net interest income | −$0.5M | −$5.9M | −$8.4M | −$8.6M | −$11.6M |
| Operating margin | −1,986.4% | −977.8% | −74.0% | 951.1% | −33.2% |
| Net income | −$55.7M | −$60.0M | −$42.9M | −$73.7M | −$27.0M |
| Net margin | −1,778.0% | −1,194.3% | −109.6% | 947.5% | −73.5% |
| Diluted EPS | −$1.60 | −$1.72 | −$1.17 | −$1.56 | −$0.56 |
| Cash | |||||
| Cash from operations | −$35.3M | −$39.0M | −$13.5M | −$21.2M | −$37.7M |
| Capital expenditure | $0.3M | $0.1M | $0.4M | $0.9M | $0.6M |
| Free cash flow | −$35.6M | −$39.1M | −$13.8M | −$22.1M | −$38.3M |
| FCF margin | −1,137.1% | −778.8% | −35.4% | 283.6% | −104.2% |
| Share count change | 42.4% | 0.3% | 6.0% | 28.0% | 1.2% |
| Debt and strength | |||||
| Cash and short-term investments | $95.0M | $44.1M | $83.2M | $51.7M | $62.0M |
| Shareholders' equity | $30.3M | −$28.8M | −$2.0M | −$68.3M | −$99.3M |
| Current ratio | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Interest coverage | −67.4x | −3.4x | −1.8x | −9.1x | −0.7x |
| Returns and quality | |||||
| Return on equity | −95.3% | −8,013.8% | — | — | — |
| Return on tangible equity | −183.5% | — | — | — | — |
| Piotroski F-score | 2 | 2 | 4 | 1 | 3 |
| Altman Z'' | −5.5 | −16.3 | −8.9 | −25.8 | −20.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nanobiotix S.A. · NBTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $34.53 a share, the company is worth $1.65T.
Source: SEC EDGAR XBRL filings (CIK 0001760854). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.